A comprehensive market research report on over-the-counter and direct-to-consumer infectious disease diagnostics forecasts significant growth through 2029, driven by rapid testing technologies, privacy concerns, and digital accessibility. The report analyzes market trends across 15 countries, covering respiratory, STD, UTI, and other infectious disease testing channels, with profiles of 70+ diagnostic companies.

The global automated sample preparation market is expected to expand at a 10.10% CAGR from 2025 to 2031, driven by pharmaceutical R&D investments, need for reproducibility, and AI/ML adoption. However, high initial costs and integration challenges with legacy systems remain significant barriers, particularly for smaller laboratories and SMEs.

The global microarrays market is projected to grow from USD 6.16 billion in 2025 to USD 10.72 billion by 2033, at a CAGR of 7.24%. Growth is driven by increasing adoption of genomics and proteomics research, drug discovery applications, and disease diagnostics. North America dominates with 43% market share, while Asia Pacific emerges as the fastest-growing region with a 9.54% CAGR.

The global next-generation sequencing (NGS) market is expected to grow from USD 14.25 billion in 2025 to USD 103.24 billion by 2035, at a CAGR of 21.9%. North America currently dominates with 50% market share, while Asia Pacific is the fastest-growing region. Oncology is the leading application segment, and consumables represent the largest product category. Key industry players are advancing NGS technology through strategic partnerships and innovative platforms.

German life sciences company Qiagen is exploring strategic options including a potential sale, with renewed takeover interest from multiple U.S.-based strategic buyers. The company has engaged advisers as its supervisory board evaluates preliminary approaches. CEO Thierry Bernard's announced departure is seen as removing a key obstacle to a deal. Qiagen has attracted acquisition interest multiple times in recent years, including failed attempts from Thermo Fisher Scientific (2020, ~$12 billion), BioMérieux (2021), and Bio-Rad Laboratories (2022).

The Middle East exosomes market is projected to grow from USD 3.07 million in 2024 to USD 20.03 million by 2033, at a CAGR of 23.38%. Growth is driven by increasing adoption of exosome-based diagnostics and therapeutics, rising biomedical R&D investment, and growing demand for liquid biopsy technologies. Key challenges include stringent regulatory requirements and high manufacturing costs.

The global reproductive genetics market is projected to grow from USD 7.31 billion in 2025 to USD 16.67 billion by 2032, with a CAGR of 12.5%. Growth is driven by rising demand for genetic testing, preimplantation genetic testing (PGT), and non-invasive prenatal testing (NIPT), though ethical and legal challenges continue to limit expansion. North America leads with 40.5% market share, while Asia Pacific is the fastest-growing region.

The global IVD diagnostic molecule raw enzymes market is projected to grow from USD 2.39 billion in 2024 to USD 4.73 billion by 2034, with a 7.13% CAGR. Key growth drivers include increasing chronic diseases, technological advancements in molecular diagnostics, and rising demand for precision medicine.

The global genomics data analysis market is projected to grow from $6.85 billion in 2024 to $28.74 billion by 2034, driven by advancements in sequencing technologies, personalized medicine demand, and AI-driven analytics.

The Automated Microbiology Market is projected to grow from $7.87 billion in 2025 to $12.52 billion by 2030, with a 9.74% CAGR, driven by demand for efficient diagnostic solutions in healthcare and industrial sectors.

The global oncology molecular diagnostics market is expected to grow from $3.48 billion in 2025 to $9.76 billion by 2034, with a 12.13% CAGR. North America currently dominates the market, with breast cancer diagnostics leading market segments and technological innovations driving growth.

The STD Diagnostic Market is projected to grow from $9.82 billion in 2024 to $17.93 billion by 2033, driven by increased STD prevalence, technological advancements, and improved healthcare accessibility.